COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Phase I Clinical Trial of DA-6886 in Healthy Male Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01633723
Recruitment Status : Unknown
Verified August 2013 by Dong-A ST Co., Ltd. ( Dong-A Pharmaceutical Co., Ltd. ).
Recruitment status was:  Recruiting
First Posted : July 4, 2012
Last Update Posted : August 13, 2013
Information provided by (Responsible Party):
Dong-A ST Co., Ltd. ( Dong-A Pharmaceutical Co., Ltd. )

Brief Summary:
DA-6886_IBS_I is a phase I, dose block-randomized, double-blind, placebo-controlled, single/multiple dosing, dose escalation clinical trial with open-labelled food effect study of single dose to investigate the safety, tolerability and pharmacokinetics of DA-6886 after oral administration in healthy male subjects.

Condition or disease Intervention/treatment Phase
Irritable Bowel Syndrome Drug: DA-6886 Drug: Placebo of DA-6886 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 88 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase I, Dose Block-randomized, Double-blind, Placebo-controlled, Single/Multiple Dosing, Dose Escalation Clinical Trial With Open-labelled Food Effect Study of Single Dose to Investigate the Safety, Tolerability and Pharmacokinetics of DA-6886 After Oral Administration in Healthy Male Subjects
Study Start Date : August 2012
Estimated Primary Completion Date : December 2013

Arm Intervention/treatment
Experimental: DA-6886 Drug: DA-6886

single dose study : DA-6886 1mg,2.5mg,5mg,10mg,20mg dosage (Dose-escalation)

multiple dose study : DA-6886 2.5mg,5mg,10mg or 5mg,10mg,20mg dosage (Dose-escalation)

Placebo Comparator: DA-6886 placebo Drug: Placebo of DA-6886
DA-6886 placebo

Primary Outcome Measures :
  1. Assessment of safety [ Time Frame: up to 7 days (single dose study, single dose study for food effect), 15 days (multiple dose study) ]
    1. Adverse Events
    2. Laboratory Results
    3. Vital sign, Physical Examination, EKG

Secondary Outcome Measures :
  1. Pharmacokinetics and Pharmacodynamics [ Time Frame: up to 48 hours after last dosing of DA-6886 ]
    Cmax, Tmax, AUClast, Ae, Cssmax, Cssmin

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • 20 ~ 45 years old
  • 27kg/m2 ≥ BMI ≥ 20kg/m2
  • Healthy Male
  • Informed consent

Exclusion Criteria:

  • Clinically significant medical history
  • smokers
  • Clinically significant hypersensitivity of Drugs
  • Clinically significant cutaneous disorder
  • QTcB > 450msec
  • have a history of drug abuse or show positive for drug abuse or cotinine at urine screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01633723

Layout table for location contacts
Contact: Kyun-Seop Bae, M.D., Ph.d. +82-2-3010-4611

Layout table for location information
Korea, Republic of
ASAN medical center Recruiting
Seoul, Songpa-gu, Korea, Republic of, 138-736
Contact: Kyun-Seop Bae, M.D., Ph.D.    +82-2-3010-4611   
Sponsors and Collaborators
Dong-A Pharmaceutical Co., Ltd.
Layout table for additonal information
Responsible Party: Dong-A Pharmaceutical Co., Ltd. Identifier: NCT01633723    
Other Study ID Numbers: DA6886_IBS_I
First Posted: July 4, 2012    Key Record Dates
Last Update Posted: August 13, 2013
Last Verified: August 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Irritable Bowel Syndrome
Colonic Diseases, Functional
Colonic Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases